Predicting drug metabolism -: An evaluation of the expert system METEOR

被引:51
作者
Testa, B [1 ]
Balmat, AL
Long, A
Judson, P
机构
[1] Univ Lausanne, Inst Med Chem, CH-1015 Lausanne, Switzerland
[2] Univ Leeds, Dept Chem, Lhasa Ltd, Leeds LS2 9HD, W Yorkshire, England
关键词
D O I
10.1002/cbdv.200590064
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The paper begins with a discussion of the goals of metabolic predictions in early drug research, and some difficulties toward this objective, mainly the various substrate and product selectivities characteristic of drug metabolism. The major in silico approaches to predict drug metabolism are then classified and summarized. A discrimination is, thus, made between 'local' and 'global' systems. In its second part, an evaluation of METEOR, a rule-based expert system used to predict the metabolism of drugs and other xenobiotics, is reported. The published metabolic data of ten substrates were used in this evaluation, the overall results being discussed in terms of correct vs. disputable (i.e., false-positive and false-negative) predictions. The predictions for four representative substrates are presented in detail (Figs. 1-4), illustrating the interest of such an evaluation in identifying where and how predictive rules can be improved.
引用
收藏
页码:872 / 885
页数:14
相关论文
共 60 条
[31]   Molecular modeling of human cytochrome P450-substrate interactions [J].
Lewis, DFV .
DRUG METABOLISM REVIEWS, 2002, 34 (1-2) :55-67
[32]   Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1) [J].
Lewis, DFV .
DRUG METABOLISM REVIEWS, 1997, 29 (03) :589-650
[33]   Frontier orbitals in chemical and biological activity: Quantitative relationships and mechanistic implications [J].
Lewis, DFV .
DRUG METABOLISM REVIEWS, 1999, 31 (03) :755-816
[34]   Screening for human ADME/Tox drug properties in drug discovery [J].
Li, AP .
DRUG DISCOVERY TODAY, 2001, 6 (07) :357-366
[35]   Role of pharmacokinetics in the discovery and development of indinavir [J].
Lin, JH .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 39 (1-3) :33-49
[36]   The metabolism and excretion of galantamine in rats, dogs, and humans [J].
Mannens, GSJ ;
Snel, CAW ;
Hendrickx, J ;
Verhaeghe, T ;
Le Jeune, L ;
Bode, W ;
van Beijsterveldt, L ;
Lavrijsen, K ;
Leempoels, J ;
Van Osselaer, N ;
Van Peer, A ;
Meuldermans, W .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (05) :553-563
[37]  
Penzotti JE, 2004, CURR OPIN DRUG DISC, V7, P49
[38]   A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors [J].
Poso, A ;
Gynther, J ;
Juvonen, R .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2001, 15 (03) :195-202
[39]   First principles investigation of singly reduced cytochrome P450 [J].
Segall, MD ;
Payne, MC ;
Ellis, SW ;
Tucker, GT ;
Eddershaw, PJ .
XENOBIOTICA, 1999, 29 (06) :561-571
[40]  
Smith DA, 1996, MED RES REV, V16, P243